LAUREN BEASLEY: Open Payments
NPI 1578183802 · COLUMBUS, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$811 in 44 payments from 11 companies in 2025. Trend: 2023 $694 · 2024 $1,020 · 2025 $811
Food & beverage: $811
| Company | Payments | Amount |
|---|---|---|
| Boston Scientific Corporation | 15 | $220 |
| Novartis Pharmaceuticals Corporation | 6 | $144 |
| AstraZeneca Pharmaceuticals LP | 5 | $91 |
| Amgen Inc. | 5 | $88 |
| Merck Sharp & Dohme LLC | 3 | $85 |
| BridgeBio Pharma, Inc. | 2 | $49 |
| E.R. Squibb & Sons, L.L.C. | 3 | $44 |
| PFIZER INC. | 2 | $35 |
| AngioDynamics, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $20 |
Products named: LEQVIO, WAINUA, Repatha, VERQUVO, CDS - MCT/CEM Monitoring, Attruby, ACCOLADE SR, VYNDAQEL.
Industry payments across MS — which companies pay providers there.
